Eisai R&d Management Co., Ltd.

Epizyme, Inc.

Hyeong Wook Choi

Kevin Wayne Kuntz

Steven Mathieu

Arani Chanda

Kristen Sanders

Francis Gerard Fang

Kuan-Chun Huang

Atsushi Endo

Robert Yu

Frances Fang

Mingde Shan

Frank Fang

Robert T Yu

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

Salt form of a human histone methyltransferase EZH2 inhibitor

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

A phosphoramidochloridate morpholino monomer of the following formula is provided: 

Substituted phosphorodiamidate morpholino oligomers

Provided herein are novel solid forms of N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-3-carboxamide hydrochloride, and related compositions and methods.

Hydrochloride salt form for EZH2 inhibition

A method of preparation of stereospecific synthesis of diastereomerically pure phosphorodiamidate morpholino oligomers (PMOs) of one of the following general formulas is provided: 

Chiral reagents for preparation of substituted phosphorodiamidate morpholino oligomers

Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1&#x2032;-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

Growing community of inventors

Andover, MA, United States of America

Hyeong Wook Choi